ETANERCEPT TREATMENT IN A RESISTANT CASE WITH PSORIATIC ARTHRITIS

ÇAPKIN E., KARKUCAK M., OZDEN G., Tosun M., Cakirbay H.

NOBEL MEDICUS, vol.7, no.1, pp.112-114, 2011 (SCI-Expanded) identifier

  • Publication Type: Article / Article
  • Volume: 7 Issue: 1
  • Publication Date: 2011
  • Journal Name: NOBEL MEDICUS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.112-114
  • Karadeniz Technical University Affiliated: Yes

Abstract

Psoriatic Arthritis (PsA) is a chronic systemic inflammatory disease characterized by joint inflammation associated with cutaneous psoriasis. As in rheumatoid arthritis and ankylosing spondylitis, the use of Anti-tumor necrosis factor (TNF)-alpha in psoriatic arthritis is a therapeutic revolution: both articular and cutaneous efficacies have been shown, and some improvement is visible on radiography. This case study demonstrates significant improvement on both laboratory measurements and clinical symptoms with TNF-alpha application for a late term PsA (with both axial and peripheral joint affected) patient, treated by long term disease-modifying antirheumatic drugs (DMARDS), with renal disorders and diffuse psoriatic eruptions with a review of current literature.